Next Article in Journal
A Comparative Quantitative LC-MS/MS Profiling Analysis of Human Pancreatic Adenocarcinoma, Adjacent-Normal Tissue, and Patient-Derived Tumour Xenografts
Previous Article in Journal
Identification of Potential Plasma Biomarkers for Abdominal Aortic Aneurysm Using Tandem Mass Tag Quantitative Proteomics
Previous Article in Special Issue
Proteomic Analysis of Histone Variants and Their PTMs: Strategies and Pitfalls
Article Menu

Export Article

Open AccessCommunication
Proteomes 2018, 6(4), 44; https://doi.org/10.3390/proteomes6040044

Inhibiting Arginine Methylation as a Tool to Investigate Cross-Talk with Methylation and Acetylation Post-Translational Modifications in a Glioblastoma Cell Line

1
Biomedical Sciences, Faculty of Health Sciences, University of Hull, HU6 7RX Hull, UK
2
Department of Neurosurgery, Hull Royal Infirmary, HU3 2JZ Hull, UK
3
Hull York Medical School, Faculty of Health Sciences, University of Hull, HU6 7RX Hull, UK
*
Author to whom correspondence should be addressed.
Received: 30 August 2018 / Revised: 2 October 2018 / Accepted: 17 October 2018 / Published: 20 October 2018
(This article belongs to the Special Issue Tools for understanding PTM crosstalk)
Full-Text   |   PDF [2277 KB, uploaded 20 October 2018]   |  

Abstract

Glioblastomas (GBM) are the most common grade 4 brain tumours; patients have very poor prognosis with an average survival of 15 months after diagnosis. Novel research lines have begun to explore aberrant protein arginine methylation (ArgMe) as a possible therapeutic target in GBM and ArgMe inhibitors are currently in clinical trials. Enzymes known as protein arginine methyltransferases (PRMT1-9) can lead to mono- or di-ArgMe, and in the latter case symmetric or asymmetric dimethylation (SDMA and ADMA, respectively). Using the most common GBM cell line, we have profiled the expression of PRMTs, used ArgMe inhibitors as tools to investigate post-translational modifications cross-talk and measured the effect of ArgMe inhibitors on cell viability. We have identified novel SDMA events upon inhibition of ADMA in GBM cells and spheroids. We have observed cross-talk between ADMA and lysine acetylation in GBM cells and platelets. Treatment of GBM cells with furamidine, a PRMT1 inhibitor, reduces cell viability in 2D and 3D models. These data provide new molecular understanding of a disease with unmet clinical needs. View Full-Text
Keywords: arginine methylation; cross-talk; glioblastoma; inhibitor; lysine acetylation arginine methylation; cross-talk; glioblastoma; inhibitor; lysine acetylation
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Samuel, S.F.; Marsden, A.J.; Deepak, S.; Rivero, F.; Greenman, J.; Beltran-Alvarez, P. Inhibiting Arginine Methylation as a Tool to Investigate Cross-Talk with Methylation and Acetylation Post-Translational Modifications in a Glioblastoma Cell Line. Proteomes 2018, 6, 44.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Proteomes EISSN 2227-7382 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top